Publications by authors named "M Matsubara"
Updates implemented in version 4 of the GlyCosmos Glycoscience Portal.
Anal Bioanal Chem
December 2024
Glycosylation, characterized by its complexity and diversity, is a common system across all domains of life. The glycosylation of proteins or lipids imparts them with structural and functional roles, ranging from development to infectious or Mendelian disease. The high-throughput-based omics data has revealed that glycans are involved in important cellular processes.
View Article and Find Full Text PDFBackground: Previously, we proposed that the immune-modified Glasgow Prognostic Score (imGPS), which adds the lymphocyte count to the mGPS, is helpful as a prognostic marker for patients with head and neck squamous cell carcinoma. In this study, we investigated the imGPS as a marker for the therapeutic effect of pembrolizumab in treating recurrent and metastatic head and neck cancer (RMHNC).
Methods: This study included RMHNC patients who were treated with pembrolizumab from December 2019 to April 2024.
Purpose: To investigate whether genetic and clinical characteristics differ depending on generations using 326 patients (male/female, 259/67; mean age, 55.4 ± 12.5 years) with simple CSC.
View Article and Find Full Text PDFArticle Synopsis
- Transoral surgery is effective for early-stage pharyngeal and laryngeal cancer, offering good local control with less invasiveness compared to external incisions, but criteria for postoperative treatment remain unclear.
- In a study of 70 patients at Gifu University Hospital, high rates of positive surgical margins were found (38.6% horizontal, 27.1% vertical), yet overall survival rates were strong, with 77.1% surviving five years post-surgery.
- Horizontal margin positivity correlated with worse outcomes, while vascular invasion wasn't significantly linked to prognosis, indicating a need for more research to establish clear postoperative treatment guidelines.
Article Synopsis
- A study looked at the safety of continuing blood thinners (warfarin and DOACs) in patients needing a stomach procedure for early cancer.
- It found that people taking warfarin didn't have any bleeding after the procedure, while some people taking DOACs did.
- The researchers suggest that it's safer to keep using warfarin and that stopping DOACs too close to the procedure can lead to more bleeding problems.